The major current therapeutic agents to treat T2D, i.e., sulfonylureas, meglitinides, metformin, glucacon-like peptide-1 agonists, insulin-sensitizing glitazones, sodium-glucose linked transporter type 2 inhibitors gliflozins and insulin when required, all improve metabolic control, but display little, if any, anti-inflammatory effects, with the interesting exception of metformin, whose anti-diabetic mechanisms of action still escape full understanding [51]. This evidence concerns the gene INS and type 2 diabetes mellitus.